Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Suven Signs Second Deal With Lilly

March 17, 2008 | A version of this story appeared in Volume 86, Issue 11

Suven Life Sciences and Eli Lilly & Co. have signed a second drug discovery collaboration in the area of small molecules that treat central nervous system disorders. Suven says it will receive research funding and possible milestone payments ranging from $19 million to $23 million per drug candidate. The two companies signed a similar deal in August 2006.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.